Viatris Inc. (VTRS)
Viatris: Indore Plant Could Boost 2026 Numbers
Viatris continues to struggle with declining sales across all regions, with Q2-2025 net sales down 7% year over year. VTRS's Indore plant issues have significantly impacted results, but a full recovery in 2026 could lead to earnings beats versus consensus estimates. Despite capital returns, persistent sales declines and lack of progress in debt reduction raise concerns about VTRS's long-term investment viability.
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript
Viatris Inc. (NASDAQ:VTRS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Theodora Mistras - Chief Financial Officer William Szablewski - Former Head of Capital Markets Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Bhavin Patel - Bank of America, Research Division David A.
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates
Viatris (VTRS) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.69 per share a year ago.
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target
The pharmaceutical company says its eye inflammation treatment didn't meet its target.
Viatris eye therapy fails to meet late-stage trial goal
Viatris said on Friday that its experimental ophthalmic ointment did not meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.
Viatris: A Contrarian Bet With Virtually No Downside
Viatris has aggressively deleveraged, now poised for growth with a robust pipeline and global presence in key markets like the US, India, and China. The company's balance sheet is much improved, dividend yield is attractive at 5.26%, and valuation is extremely low versus sector peers. Upcoming FDA approvals and 11 key pipeline assets could drive rapid earnings growth and a major stock price re-rating toward $20 per share.
Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Conference Call Participants Unidentified Analyst Great.
